Glenmark Pharmaceuticals Sees 10.03% Rise in Open Interest Amid Increased Trading Activity

Glenmark Pharmaceuticals Ltd. has experienced a notable increase in open interest today, signaling heightened activity in its trading. The latest open interest stands at 83,818 contracts, reflecting a rise of 7,638 contracts or 10.03% from the previous open interest of 76,180. This surge comes alongside a trading volume of 116,994 contracts, indicating robust market engagement.
In terms of price performance, Glenmark Pharmaceuticals has underperformed its sector by 1.2%, with the stock recording a 1D return of -1.87%. Over the past two days, the stock has seen a consecutive decline, totaling a drop of 3.02%. The intraday low reached Rs 1,818, marking a decrease of 2.72% from previous levels.

Despite these challenges, the stock remains liquid, with a delivery volume of 25.21 lakh shares on November 17, which is a significant increase of 260.57% compared to the five-day average. Glenmark Pharmaceuticals, operating within the Pharmaceuticals & Biotechnology sector, holds a market capitalization of Rs 52,005 crore, positioning it as a mid-cap player in the industry. Overall, the increase in open interest reflects a dynamic trading environment for Glenmark Pharmaceuticals, amidst its recent price fluctuations.